Impact of (Neo)Adjuvant Therapy Associating Anthracyclines and Taxanes With or Without Trastuzumab on Skeletal Muscle in Breast Cancer Patients

Impact of (Neo)Adjuvant Therapy Associating Anthracyclines and Taxanes With or Without Trastuzumab on Skeletal Muscle in Breast Cancer Patients

This is an interventional, prospective and monocentric study. This study includes the evaluation before and after (neo)adjuvant therapy of :

• one group of patients receiving anthracyclines and taxanes
• a second group of patients receiving anthracyclines, taxanes and trastuzumab.

Inclusion Criteria:

For group 1 without trastuzumab :

• Patients must be ≥ 18 years old
• Patients with breast cancer stage I to III
• Patients who will receive (neo)adjuvant anthracyclines and weekly taxane, without trastuzumab
• Patients must have a social security coverage
• Patients able to speak, read and understand French

For group 2 with trastuzumab :

• Patients must be ≥ 18 years old
• Patients with breast cancer grade I to III
• Patients who will receive (neo)adjuvant anthracyclines and weekly taxane, with trastuzumab
• Patients must have a social security coverage
• Patients able to speak, read and understand French

Exclusion Criteria:

• History of cancer
• Previous chemotherapy
• Patients with known chronic pathology (musculoskeletal disorders, autoimmune, vascular or neuromuscular disease)
• Pacemaker implantation
• Contraindication to physical condition evaluation
• Contraindication to local anesthesia required for microbiopsy
• Patients < 18 years old or patients ≥ 18 years old under guardianship, or supervision
• Psychiatric, musculoskeletal or neurologic disorders
• Women that are pregnant or breast-feeding